基本信息
浏览量:0
职业迁徙
个人简介
CURRENT POSITION
Head of the Department of Clinical Neurosciences at UCL Institute of Neurology (ION), Professor of Neurology and Consultant Neurologist at the National Hospital for Neurology and Neurosurgery (NHNN) and the Royal Free Hospital.
BIOGRAPHICAL PROFILE
Undergraduate training as a Scholar at Westminster Medical School. Completed post-graduate training in London and was appointed to the University Chair of Clinical Neurosciences in 1990. Currently Vice Dean of the University College London Medical School, and Director of the Royal Free Campus. Visiting Professor at Harvard in 2009 and at Yale in 2010. Co-Editor in Chief of the European Journal of Neurology, and is on several Editorial Boards of neurology and neuroscience journals. Elected a Fellow of the Academy of Medical Sciences in 1999.
RESEARCH INTERESTS
Main research interests are in neurodegeneration and are focussed on the molecular pathogenesis of Parkinson’s disease (PD) and in the development of drugs for slowing the progress of this disease. Basic science expertise includes mitochondrial biology, and his group was the first to identify mitochondrial abnormalities as a contributing factor to the pathogenesis of Parkinson’s disease. He direct a large group investigating the interaction of PINK1, parkin and alpha synuclein mutations in PD and how these lead to neuronal dysfunction and death, and the biochemical relationship between glucocerebrosidase mutations and an increased risk for PD. His clinical research is focussed on PD and encompasses both symptomatic and disease modifying therapies. Principal investigator on several international clinical trials in the development of novel symptomatic treatments for PD and neuroprotection studies. Currently leading research on the clinical phenotype of patients at risk of developing PD including those with glucocerebrosidase mutations. This work is designed to identify clinical and biochemical features of prodromal PD. Co-Principal Investigator on the MRC-Wellcome Strategic Award in Neurodegeneration (6 million) and on the Wolfson Award (£20 million)
Head of the Department of Clinical Neurosciences at UCL Institute of Neurology (ION), Professor of Neurology and Consultant Neurologist at the National Hospital for Neurology and Neurosurgery (NHNN) and the Royal Free Hospital.
BIOGRAPHICAL PROFILE
Undergraduate training as a Scholar at Westminster Medical School. Completed post-graduate training in London and was appointed to the University Chair of Clinical Neurosciences in 1990. Currently Vice Dean of the University College London Medical School, and Director of the Royal Free Campus. Visiting Professor at Harvard in 2009 and at Yale in 2010. Co-Editor in Chief of the European Journal of Neurology, and is on several Editorial Boards of neurology and neuroscience journals. Elected a Fellow of the Academy of Medical Sciences in 1999.
RESEARCH INTERESTS
Main research interests are in neurodegeneration and are focussed on the molecular pathogenesis of Parkinson’s disease (PD) and in the development of drugs for slowing the progress of this disease. Basic science expertise includes mitochondrial biology, and his group was the first to identify mitochondrial abnormalities as a contributing factor to the pathogenesis of Parkinson’s disease. He direct a large group investigating the interaction of PINK1, parkin and alpha synuclein mutations in PD and how these lead to neuronal dysfunction and death, and the biochemical relationship between glucocerebrosidase mutations and an increased risk for PD. His clinical research is focussed on PD and encompasses both symptomatic and disease modifying therapies. Principal investigator on several international clinical trials in the development of novel symptomatic treatments for PD and neuroprotection studies. Currently leading research on the clinical phenotype of patients at risk of developing PD including those with glucocerebrosidase mutations. This work is designed to identify clinical and biochemical features of prodromal PD. Co-Principal Investigator on the MRC-Wellcome Strategic Award in Neurodegeneration (6 million) and on the Wolfson Award (£20 million)
研究兴趣
论文共 442 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Alexander Balck,Max Borsche,Philip Campbell, Xi Luo, John Harvey, Theresa Brückmann, Charlotte Ludwig,Amy Harms,Katja Lohmann,Huw R Morris,Anthony H Schapira,Thomas Hankemeier,
medrxiv(2024)
Annika Kluge,Max Borsche, Linn Streubel-Gallasch,Tuğçe Gül, Susen Schaake,Alexander Balck,Jannik Prasuhn,Philip Campbell,Huw R Morris,Anthony H Schapira,Katja Lohmann,Norbert Brüggemann,
Annals of neurology (2024)
NEURAL REGENERATION RESEARCHno. 4 (2024): 725-727
Kunitoshi Takeda,Toru Watanabe,James R. Smith, David Vesey, Nathalie Tiberghien,Sian Lewis,Ben Powney,Anthony H. V. Schapira,Tamaki Hoshikawa, Andrew K. Takle
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2023): 129531-129531
The Lancet Neurologyno. 8 (2023): 661-671
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn